Furthermore, the baseline clinical information table revealed correlations between high MAD2L2 expression and glioma grade, IDH mutation status, and 1P19q co-deletion status (Additional file 2: Table S2–S4). This evidence concerns the gene MAD2L2 and central nervous system cancer.